{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307300","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.667467+00:00","generated_at":"2026-06-21T03:15:34.382950+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Agios adopts performance-based cash bonus for CMO tied to ENERGIZE trial milestone","bullets":["Dr. Sarah Gheuens, CMO and Head of R&D, eligible for up to 1.25x her 2022 target bonus ($309,375) if ENERGIZE trial milestone achieved by April 2024.","If milestone achieved before April 2024, bonus increases to 1.2x the baseline amount, totaling $371,250.","Bonus payment contingent on Dr. Gheuens remaining employed at time of milestone achievement.","CEO, CFO, and Chief Commercial Officer are not eligible for this bonus plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307300","json":"https://secwatch.observer/filing/0001193125-22-307300.json","markdown":"https://secwatch.observer/filing/0001193125-22-307300.md","text":"https://secwatch.observer/filing/0001193125-22-307300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522307300/0001193125-22-307300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312522307300/d428911d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:15:34.382950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}